Validation by Type of Method - Analytical Validation - page 164

35. Viswanathan, C. T., Bansal, S., Booth, B., DeStafano, A. J., Rose, M. J., Sailstad, J.,
Shah, V. P., Skelly, J. P., Swann, P. G., and Weiner, R., Workshop/Conference Report—
Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for
Chromatographic and Ligand Binding Assays. AAPS J. , 9(1), 2007, E30. See also www.
aapsj.org.
36. Guidance for Industry, Bioanalytical Method Validation, USFDA-CDER (May 2001),
http://www.fda.gov/cder/guidance/4252fnl.pdf.
37. Viswanathan, C. T., Bansal, S., Booth, B., DeStafano, A. J., Rose, M. J., Sailstad, J.,
Shah, V. P., Skelly, J. P., Swann, P. G., and Weiner, R., AAPS J. , 9(1), 2007, E30. See also
www.aapsj.org.
38. Hancock B, Editor. New Methods in Peptide Mapping for the Characterization of
Proteins . CRC Press, Boca Raton, FL, 1996.
39. The United States Pharmacopeia 34/National Formulary 29 (The United States
Pharmacopeial Convention, Inc., Rockville, MD, 2011), Chapter <1047>.
40. Mark-Varga, G. and Oroszlan, P., Editors, in Emerging Technologies in Protein and
Genomic Material Analysis , Journal of Chromatography Library , 68, 188, 2003,
Elsevier, Amsterdam.
41. Bongers, J., Cummings, J. J., Ebert, M. B., Federici, M. M., Gledhill, L., Gulati, D.,
Hilliard, G. M., Jones, B. H., Lee, K. R., Mozdzanowski, J., Naimoli, M., and Burman,
S., Validation of a peptide mapping method for a therapeutic monoclonal antibody: what
could we possibly learn about a method we have run 100 times? J. Pharm. Biomed.
Anal ., 21, 1099, 2000.
42. Code of Federal Regulations (CFR) 133.4, 1963.
43. Code of Federal Regulations (CFR) 211.67, 1978.
44. Valvis, I. I. and Champion, W. L. Jr., Cleaning and decontamination of potent com-
pounds in the pharmaceutical Industry. Org. Process Res. Dev. , 3, 44-52, 1999.
45. Harder, S. W., The validation of cleaning procedures. Pharm. Technol . 8(5), 29-34, 1987.
46. Smith, J. A., A modified swabbing technique for validation of detergent residues in
clean-in-place systems. Pharm. Technol . 16(1), 60-66, 1992.
47. Fourman, G. L. and Mullen, M. V., Determining cleaning validation acceptance limits
for pharmaceutical manufacturing. Pharm. Technol . 17(4), 54-60, 1993.
48. Zeller, A. O., Cleaning validation and residue limits: A contribution to current discus-
sions. Pharm. Technol . 17(10), 70-80, 1993.
49. I. Losoxantrone., Shea J. A., Shamrock, W. F., Abboud C. A., Woodeshick R. W.,
Nguyen L. Q., Rubino J. T., and Segretario, J., Validation of cleaning procedures for
highly potent drugs. Pharm. Dev. Technol . 1(1), 69-75, 1996.
50. Cleaning Validation Reprints from the Journal of Validation Technology , published by
the Institute of Validation Technology, Royal Palm Beach, FL, 1998.
51. Guide to Inspections; Validation of Cleaning Processes, at www.fda.gov/ICECI/
inspections/ inspectionguides/ucm074922.htm.
52. Guidance for Industry; Manufacturing, Processing, or Holding Active Pharmaceutical
Ingredients, p. 9-10, at www.fda.gov/downloads/drugs/guidancecomplianceregulatory
information/guidances/ucm070289.pdf.